Feijóo Montserrat, Túnez Isaac, Tasset Inmaculada, Montilla Pedro, Pérez-Guijo Verónica, Muñoz-Gomariz Elisa, Ruiz Adela, Schiotis Ruxandra, Collantes Eduardo
Departamento de Bioquímica y Biología Molecular, Facultad de Medicina, Universidad de Córdoba, Córdoba, Spain.
Pharmacology. 2009;83(4):211-6. doi: 10.1159/000200022. Epub 2009 Feb 7.
The present study evaluated the effect of infliximab on the myeloperoxidase (MPO) concentration in chronic inflammatory joint disease. Eighteen patients were divided into active and inactive groups. Erythrocyte sedimentation rate, C-reactive protein, white blood cell counts, MPO concentration, and biomarkers of oxidative stress were measured before and after the infusion of infliximab. Patients with active disease showed increases in concentrations of MPO and biomarkers of oxidation, but decreases in antioxidant parameters. After infliximab treatment, both inflammatory parameters and MPO concentrations were normalized.
(1) the MPO concentration is related to inflammatory activity and could play an important role in the maintenance and outbreak of oxidative stress present in these diseases, and (2) infliximab inhibits MPO concentration.
本研究评估了英夫利昔单抗对慢性炎症性关节病中髓过氧化物酶（MPO）浓度的影响。18名患者被分为活动组和非活动组。在输注英夫利昔单抗前后，测量了红细胞沉降率、C反应蛋白、白细胞计数、MPO浓度和氧化应激生物标志物。患有活动性疾病的患者MPO浓度和氧化生物标志物增加，但抗氧化参数降低。英夫利昔单抗治疗后，炎症参数和MPO浓度均恢复正常。
（1）MPO浓度与炎症活动相关，可能在这些疾病中存在的氧化应激的维持和爆发中起重要作用；（2）英夫利昔单抗可抑制MPO浓度。
